The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives
Smart Medicine · 2025-06 · 4 (2)
DOI: 10.1002/smmd.70010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Smart Medicine, online erschienen am 19.05.2025. Verfasst von Jiafu Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Affiliated Sixth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The research of primary urological cancers, including bladder cancer (BCa), prostate cancer (PCa), and renal cancer (RCa), has developed rapidly. Microfluidic technology provides a good variety of benefits compared to the heterogeneity of animal models and potential ethical issues of human study. Microfluidic technology and its application with cell culture (e.g., organ‐on‐a‐chip, OOC) are extensively used in urological cancer studies in preclinical and clinical settings. The application has provided diagnostic and therapeutic benefits for patients with urological diseases, especially by evaluating biomarkers for urinary malignancies. In this review, we go through the applications of OOC in BCa, Pca and Rca, and discuss the prospects of reducing the cost and improving the repeatability and amicability of the intelligent integration of urinary system organ chips.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Affiliated Sixth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
- School of Materials Science and Engineering Shanghai University of Engineering Science Shanghai China.
- Institute for Personalized Medicine School of Biomedical Engineering Shanghai Jiao Tong University Shanghai China.
- National Engineering Research Center for Nanotechnology Shanghai China.
- Department of Pathology Henry Ford Hospital Detroit Michigan USA.
- Wake Forest Institute for Regenerative Medicine Winston-Salem North Carolina USA.
ORCID-Profile: Wenguo Cui
Zitieren
APA
Liu, J., Zhi, X., Fang, X., Li, W., Zhao, W., Liu, M., Lai, E., Fang, W., Wang, J., Zheng, Y., Zou, J., Fu, Q., Cui, W., & Zhang, K. (2025). The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives. Smart Medicine, 4(2). https://doi.org/10.1002/smmd.70010
Vancouver
Liu J, Zhi X, Fang X, Li W, Zhao W, Liu M, et al. The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives. Smart Medicine. 2025;4(2). doi:10.1002/smmd.70010
BibTeX
@article{Liu2025,
author = {Liu, Jiafu and Zhi, Xiao and Fang, Xiaolan and Li, Wenyao and Zhao, Weixin and Liu, Meng and Lai, Enping and Fang, Wenzhuo and Wang, Juan and Zheng, Yu and Zou, Jiang and Fu, Qiang and Cui, Wenguo and Zhang, Kaile},
title = {The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives},
journal = {Smart Medicine},
year = {2025},
volume = {4},
number = {2},
doi = {10.1002/smmd.70010}
}
EUVIMED